These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 28724846

  • 1. Metabolic and Inflammatory Changes with Orlistat and Sibutramine Treatment in Obese Malaysian Subjects.
    Al-Tahami BAM, Al-Safi Ismail AA, Sanip Z, Yusoff Z, Shihabudin TMT, Singh TSP, Rasool AHG.
    J Nippon Med Sch; 2017; 84(3):125-132. PubMed ID: 28724846
    [Abstract] [Full Text] [Related]

  • 2. [Pharmacological therapy of obesity].
    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [Abstract] [Full Text] [Related]

  • 3. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
    Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF.
    Fundam Clin Pharmacol; 2011 Oct; 25(5):642-51. PubMed ID: 21077943
    [Abstract] [Full Text] [Related]

  • 4. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.
    Derosa G, Cicero AF, D'Angelo A, Fogari E, Maffioli P.
    J Clin Pharm Ther; 2012 Apr; 37(2):187-95. PubMed ID: 21812797
    [Abstract] [Full Text] [Related]

  • 5. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients.
    Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, Cicero AF.
    J Clin Pharm Ther; 2011 Oct; 36(5):592-601. PubMed ID: 21070297
    [Abstract] [Full Text] [Related]

  • 6. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes.
    Tong PC, Lee ZS, Sea MM, Chow CC, Ko GT, Chan WB, So WY, Ma RC, Ozaki R, Woo J, Cockram CS, Chan JC.
    Arch Intern Med; 2002 Nov 25; 162(21):2428-35. PubMed ID: 12437401
    [Abstract] [Full Text] [Related]

  • 7. Impact of weight loss on adipocytokines, C-reactive protein and insulin sensitivity in hypertensive women with central obesity.
    Borges RL, Ribeiro-Filho FF, Carvalho KM, Zanella MT.
    Arq Bras Cardiol; 2007 Dec 25; 89(6):409-14. PubMed ID: 18317625
    [Abstract] [Full Text] [Related]

  • 8. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF.
    Expert Opin Pharmacother; 2010 Aug 25; 11(12):1971-82. PubMed ID: 20569086
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
    Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, BascilTutuncu N, Guvener N.
    Diabetes Obes Metab; 2002 Jan 25; 4(1):49-55. PubMed ID: 11874442
    [Abstract] [Full Text] [Related]

  • 10. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.
    Diabetes Nutr Metab; 2004 Aug 25; 17(4):222-9. PubMed ID: 15575343
    [Abstract] [Full Text] [Related]

  • 11. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women.
    Bougoulia M, Triantos A, Koliakos G.
    Hormones (Athens); 2006 Aug 25; 5(4):259-69. PubMed ID: 17178701
    [Abstract] [Full Text] [Related]

  • 12. Obesity indices and metabolic markers are related to hs-CRP and adiponectin levels in overweight and obese females.
    Sanip Z, Ariffin FD, Al-Tahami BA, Sulaiman WA, Rasool AH.
    Obes Res Clin Pract; 2013 Aug 25; 7(4):e315-20. PubMed ID: 24306161
    [Abstract] [Full Text] [Related]

  • 13. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines.
    Valsamakis G, McTernan PG, Chetty R, Al Daghri N, Field A, Hanif W, Barnett AH, Kumar S.
    Metabolism; 2004 Apr 25; 53(4):430-4. PubMed ID: 15045687
    [Abstract] [Full Text] [Related]

  • 14. Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.
    Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, Cicero AF.
    J Pharm Pharm Sci; 2010 Apr 25; 13(3):378-90. PubMed ID: 21092710
    [Abstract] [Full Text] [Related]

  • 15. [Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial].
    Tong NW, Ran XW, Li QF, Tang BD, Li R, Yang FY, Liu YP, Li XJ.
    Zhonghua Nei Ke Za Zhi; 2005 Sep 25; 44(9):659-63. PubMed ID: 16202254
    [Abstract] [Full Text] [Related]

  • 16. Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients?
    Aydin N, Topsever P, Kaya A, Karasakal M, Duman C, Dağar A.
    Tohoku J Exp Med; 2004 Mar 25; 202(3):173-80. PubMed ID: 15065643
    [Abstract] [Full Text] [Related]

  • 17. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.
    Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB.
    Rom J Gastroenterol; 2003 Sep 25; 12(3):189-92. PubMed ID: 14502318
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.
    Kaya A, Aydin N, Topsever P, Filiz M, Oztürk A, Dağar A, Kilinç E, Ekmekcioglu C.
    Biomed Pharmacother; 2004 Dec 25; 58(10):582-7. PubMed ID: 15589067
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
    Chou KM, Huang BY, Fanchiang JK, Chen CH.
    Chang Gung Med J; 2007 Dec 25; 30(6):538-46. PubMed ID: 18350737
    [Abstract] [Full Text] [Related]

  • 20. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
    Faria AN, Ribeiro Filho FF, Kohlmann NE, Gouvea Ferreira SR, Zanella MT.
    Diabetes Obes Metab; 2005 May 25; 7(3):246-53. PubMed ID: 15811141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.